Ожирение и метаболизм (Dec 2020)

Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review

  • M. Yu. Yukina,
  • M. O. Chernova,
  • N. F. Nuralieva,
  • A. K. Eremkina,
  • E. A. Troshina,
  • G. A. Melnichenko,
  • N. G. Mokrysheva

DOI
https://doi.org/10.14341/omet12700
Journal volume & issue
Vol. 17, no. 4
pp. 357 – 368

Abstract

Read online

Adrenal insufficiency (AI) is a syndrome caused by disturbance in the synthesis and secretion of hormones of the adrenal cortex, which ensure the vital activity, energy and water-salt homeostasis. The widest hormonal deficiency is observed in primary hypocorticism, when the synthesis of not only glucocorticoids (GC) and adrenal androgens, but also mineralocorticoids is disrupted. Lifelong replacement therapy with GCs for this pathology may be associated with a risk of bone loss and osteoporosis. However, at present, there are no clear guidelines for diagnosis of bone condition, including and bone mineral density (BMD) monitoring during treatment with GCs in patients with AI. This review summarizes collected data on the key pathogenetic links of glucocorticoid-induced osteoporosis, incidence of decreased BMD and fractures in patients with AI. In this review factors that influence bone metabolism in this cohort of patients are considered: the type and the dose of prescribed GCs, the type (primary, secondary, HH in congenital adrenal cortex dysfunction) and the duration of AI, age, gender, and the presence of concomitant endocrine disorders (hypogonadism, growth hormone (GH) deficiency). In addition, the review presents data on the effect of adrenal androgen replacement therapy and recombinant GH therapy on bone metabolism in secondary AI.

Keywords